GTx-024: Clinical Trials

7 trials of GTx-024, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 2 withdrawn, 1 terminated. 7 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 27Completed 4, Withdrawn 2, Terminated 1

Follow GTx-024: new trials by email Literature Review of GTx-024 trials Research Report on GTx-024

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study to Assess Long-Term Safety/Tolerability of Enobosarm (GTx 024) in Stress Urinary Incontinence
GTx-024 - Stress Urinary Incontinence
Phase 2WithdrawnGTx2018-06-282024-03-01
Durability Extension Study to Assess Clinical Activity and Safety of Enobosarm (GTx-024) in Stress Urinary Incontinence
GTx-024, Matching Placebo - Stress Urinary Incontinence
Phase 2WithdrawnGTx2018-05-282023-09-14
Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer
Enobosarm, Laboratory Biomarker Analysis, Pembrolizumab - Androgen Receptor Positive, Estrogen Receptor Negative
Phase 2CompletedCity of Hope Medical Center182017-06-012024-02-20
GTx-024 as a Treatment for Stress Urinary Incontinence in Women
GTx-024 - Stress Urinary Incontinence
Phase 2CompletedGTx192016-01-012021-02-01
Efficacy and Safety of GTx-024 in Patients With Estrogen Receptor (ER)+/Androgen Receptor (AR)+ Breast Cancer
GTx-024 - ER+ and AR+ Breast Cancer
Phase 2CompletedGTx1362015-08-012020-12-09
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
GTx-024 - Triple Negative Breast Cancer
Phase 2TerminatedGTx322015-06-012020-11-18
Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.
GTx-024, Placebo - Cachexia
Phase 2CompletedGTx1592007-05-012014-07-11

Conditions studied

Urinary Incontinence, Stress (3)  ·  Triple Negative Breast Neoplasms (2)  ·  Cachexia (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Colorectal Neoplasms (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Muscular Atrophy (1)

Sponsors

GTx (6)  ·  City of Hope Medical Center (1)

Countries

United States (7)  ·  Canada (1)

Top investigators

Kenneth Peters, MD (2)  ·  Beth A Overmoyer, MD (1)  ·  Hope S Rugo, MD (1)  ·  Kenneth M. Peters, MD (1)  ·  Yuan Yuan (1)

Results publications

PMID 23499390, PMID 38342115